Daniel Meraviglia-Crivelli

448 total citations
11 papers, 323 citations indexed

About

Daniel Meraviglia-Crivelli is a scholar working on Molecular Biology, Oncology and Immunology. According to data from OpenAlex, Daniel Meraviglia-Crivelli has authored 11 papers receiving a total of 323 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Molecular Biology, 4 papers in Oncology and 4 papers in Immunology. Recurrent topics in Daniel Meraviglia-Crivelli's work include Advanced biosensing and bioanalysis techniques (5 papers), CAR-T cell therapy research (4 papers) and RNA Interference and Gene Delivery (4 papers). Daniel Meraviglia-Crivelli is often cited by papers focused on Advanced biosensing and bioanalysis techniques (5 papers), CAR-T cell therapy research (4 papers) and RNA Interference and Gene Delivery (4 papers). Daniel Meraviglia-Crivelli collaborates with scholars based in Spain, United States and Austria. Daniel Meraviglia-Crivelli's co-authors include Fernando Pastor, Beatriz Moreno, Mario Martínez Soldevilla, Fernando Cartón‐García, Helena Villanueva, María Villalba, Hisse M. van Santen, Santos Mañes, Isabel Mérida and Antonia Ávila‐Flores and has published in prestigious journals such as Molecular Cancer, Molecular Therapy and Cancers.

In The Last Decade

Daniel Meraviglia-Crivelli

11 papers receiving 317 citations

Peers

Countries citing papers authored by Daniel Meraviglia-Crivelli

Since Specialization

Citations

This map shows the geographic impact of Daniel Meraviglia-Crivelli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Meraviglia-Crivelli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Meraviglia-Crivelli more than expected).

Fields of papers citing papers by Daniel Meraviglia-Crivelli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Meraviglia-Crivelli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Meraviglia-Crivelli. The network helps show where Daniel Meraviglia-Crivelli may publish in the future.

Co-authorship network of co-authors of Daniel Meraviglia-Crivelli

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Meraviglia-Crivelli. A scholar is included among the top collaborators of Daniel Meraviglia-Crivelli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Meraviglia-Crivelli. Daniel Meraviglia-Crivelli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

#	Work	Indexed citations
1	CD3 aptamers promote expansion and persistence of tumor-reactive T cells for adoptive T cell therapy in cancer 2024 ·Molecular Therapy — Nucleic Acids ·(unknown), (unknown), Daniel Meraviglia-Crivelli, Hisse M. van Santen, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Eva Sevcsik, (unknown), Fernando Pastor	2
2	Modulating T Cell Responses by Targeting CD3 2023 ·Cancers ·(unknown), Beatriz Moreno, Daniel Meraviglia-Crivelli, (unknown), Helena Villanueva, (unknown), (unknown), Hisse M. van Santen, Fernando Pastor	42
3	A pan-tumor-siRNA aptamer chimera to block nonsense-mediated mRNA decay inflames and suppresses tumor progression 2022 ·Molecular Therapy — Nucleic Acids ·Daniel Meraviglia-Crivelli, Helena Villanueva, (unknown), (unknown), Beatriz Moreno, María Villalba, Fernando Pastor	18
4	IL-6/STAT3 signaling in tumor cells restricts the expression of frameshift-derived neoantigens by SMG1 induction 2022 ·Molecular Cancer ·Daniel Meraviglia-Crivelli, Helena Villanueva, (unknown), María Villalba, Beatriz Moreno, (unknown), Alfonso Calvo, (unknown), (unknown), Igor Ruiz de los Mozos, (unknown), Fernando Pastor	19
5	Therapeutic Strategies to Enhance Tumor Antigenicity: Making the Tumor Detectable by the Immune System 2022 ·Biomedicines ·Daniel Meraviglia-Crivelli, (unknown), (unknown), Beatriz Moreno, Helena Villanueva, Fernando Pastor	11
6	Oligonucleotide-Based Therapies for Renal Diseases 2021 ·Biomedicines ·Fernando Cartón‐García, (unknown), Daniel Meraviglia-Crivelli, Rafael Aldabe, Fernando Pastor	14
7	Aptamers Against Live Targets: Is In Vivo SELEX Finally Coming to the Edge? 2020 ·Molecular Therapy — Nucleic Acids ·(unknown), (unknown), Beatriz Moreno, Daniel Meraviglia-Crivelli, Mario Martínez Soldevilla, Fernando Cartón‐García, Fernando Pastor	95
8	ICOS Costimulation at the Tumor Site in Combination with CTLA-4 Blockade Therapy Elicits Strong Tumor Immunity 2019 ·Molecular Therapy ·Mario Martínez Soldevilla, Helena Villanueva, Daniel Meraviglia-Crivelli, (unknown), Marta Ruiz, (unknown), María Villalba, Beatriz Moreno, Teresa Lozano, Diana Llópiz, Álvaro Pejenaute, Pablo Sarobe, Fernando Pastor	43
9	Diacylglycerol kinase α inactivation is an integral component of the costimulatory pathway that amplifies TCR signals 2018 ·Cancer Immunology Immunotherapy ·(unknown), (unknown), (unknown), (unknown), Daniel Meraviglia-Crivelli, Santos Mañes, Isabel Mérida, Antonia Ávila‐Flores	28
10	Intratumoral injection of activated B lymphoblast in combination with PD-1 blockade induces systemic antitumor immunity with reduction of local and distal tumors 2018 ·OncoImmunology ·Mario Martínez Soldevilla, Helena Villanueva, Naiara Martínez-Vélez, Daniel Meraviglia-Crivelli, Marta M. Alonso, (unknown), (unknown), Montse Puigdelloses, Fernando Pastor	9
11	Aptamer-iRNAs as Therapeutics for Cancer Treatment 2018 ·Pharmaceuticals ·Mario Martínez Soldevilla, Daniel Meraviglia-Crivelli, (unknown), Fernando Pastor	42

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact